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Abstract: Stroke is one of the major culprits responsible for morbidity and mortality worldwide, and
the currently available pharmacological strategies to combat this global disease are scanty. Cation-
chloride cotransporters (CCCs) are expressed in several tissues (including neurons) and extensively
contribute to the maintenance of numerous physiological functions including chloride homeostasis.
Previous studies have implicated two CCCs, the Na+-K+-Cl− and K+-Cl− cotransporters (NKCCs and
KCCs) in stroke episodes along with their upstream regulators, the with-no-lysine kinase (WNKs)
family and STE20/SPS1-related proline/alanine rich kinase (SPAK) or oxidative stress response
kinase (OSR1) via a signaling pathway. As the WNK-SPAK/OSR1 pathway reciprocally regulates
NKCC and KCC, a growing body of evidence implicates over-activation and altered expression of
NKCC1 in stroke pathology whilst stimulation of KCC3 during and even after a stroke event is
neuroprotective. Both inhibition of NKCC1 and activation of KCC3 exert neuroprotection through
reduction in intracellular chloride levels and thus could be a novel therapeutic strategy. Hence,
this review summarizes the current understanding of functional regulations of the CCCs implicated
in stroke with particular focus on NKCC1, KCC3, and WNK-SPAK/OSR1 signaling and discusses
the current and potential pharmacological treatments for stroke.
Keywords: stroke; electroneutral transport; cation-chloride cotransporters; KCCs; NKCCs;
WNK-SPAK/OSR1
1. Introduction of Cation-Chloride Cotransporter Family
The family of cation-chloride cotransporters (CCCs) comprises the Na+-K+-Cl−, Na+-
Cl−, and K+-Cl− cotransporters (NKCCs, NCC, and KCCs). Identification of these CCCs
in several tissues such as red blood cells, epithelia, and neurons have alluded to their
extensive contributions to ion and water homeostasis, both at a cellular and trans-epithelial
level [1–3]. The identification of the functional properties of most of these transporters dates
back to the late 1970s and early 1980s as Cl−-dependent cation fluxes, with red blood cells
and Ehrlich ascites tumor cells constituting pivotal model tissues [4–7]. Subsequently, their
molecular identities were established about a decade afterwards [8–10]. CCCs are intrinsic
membrane proteins that move Na+, K+, and Cl− ions across plasma membranes in a tightly
coupled electroneutral manner. They facilitate secondary active transport driven by the
gradients generated by the Na+/K+-ATPase [11]. The solute carrier family 12 (SLC12) of
the CCC family consists of nine members [2]. A group of three Na+-dependent inward
cotransporters comprises of one Na+-Cl− cotransporter (NCC)—its sole isoform is found
in the kidney and encoded by SLC12A3 [9] and two Na+-K+-Cl− cotransporters isoforms
(NKCC1 and 2)—NKCC1 is ubiquitous whilst NKCC2 is specifically expressed in the
kidney and are encoded by SLC12A2 and SLC12A1, respectively [2]. Na+-independent
outward transport of K+ and Cl− is facilitated by four K+-Cl− cotransporters with distinct
functional properties (KCC1 [12], KCC2 [13], KCC3, and KCC4 [14,15]). The KCC isoforms
are encoded by SLC12A4–7 respectively, of which SLC12A5 (KCC2) is found exclusively in
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neurons [2]. The additional SLC12 family members, CCC9 and CCC-interacting protein
(CIP), are encoded by SLC12A8 and SLC12A9, respectively, and have no physiological role
ascribed to them yet [16], though recent genome-wide association studies found novel
SLC12A8 variants may be associated with dyslipidemia [17], and SLC12A9 may be involved
in feather pecking and aggressive behavior [18] (see Table 1).
All proteins in the CCC family have common functional characteristics. These include
(1) the coupled transport of one cation (Na+ and/or K+) per individually transported anion,
hence the appellation of electroneutral cotransporters, (2) chloride is always the transported
anion, (3) all cotransporters are modulated by variations in cell volume, (4) changes in
the intracellular chloride concentration ([Cl−]i) influence the modulation of their expres-
sion, and (5) the regulation of CCCs activity is achieved through phosphorylation and
dephosphorylation processes [19]. The functional and structural characteristics of the Na+
dependent and Na+ independent branches clearly distinguish the two. The degree of
identity amongst the Na+ dependent transporters and the Na+ independent are 50% and
70% respectively. Between the two NKCC isoforms, the degree of identity is 25% [20].
Stroke is one of the major culprits responsible for global death and disability [21].
Currently, there is a paucity of pharmacological strategies to reduce the mental damage
as well as the burden triggered by this pathology. Ischemic stroke is the most common
type of stroke, which accounts for approximately 85% of the cases of the pathology [22].
Ischemia is the disruption of blood flow and the subsequent depletion of oxygen and
glucose. As neuronal components strictly function on aerobic metabolism [23], an ischemia
in the brain leads to reduced available ATP levels and ionic imbalance across the neuronal
cell membrane [24], which causes irreversible neuronal death, also known as ischemic
stroke [25–27]. During this process, an imbalance of excitatory glutamate and inhibitory
gamma amino acid butyric acid (GABA) further accelerate neuronal demise [28–30], subse-
quently leading to the onset of post-stroke seizures [20,31,32]. Neuronal cells excitation is
opposed by inhibitory GABA through the activation of GABAA receptors. The activation of
the GABAA receptors is dependent on the chloride transmembrane gradient [23]. Notably,
CCCs are the primary regulators of chloride homeostasis in the brain [2,33]. This role is
accomplished through the extrusion of Cl− via KCC2 and entry of Cl− via NKCC1 which
regulates [Cl−]i. GABA is inhibitory as a result of lower [Cl−]I, driven by higher expression
of KCC2. Interestingly, immature neurons express less KCC2 and more NKCC1 leading
to a higher [Cl−]i and excitatory GABA. The switch from excitatory to inhibitory during
neurodevelopment, a process termed excitatory-to-inhibitory GABA switch, is generated
through reduction in NKCC1 level and increase in KCC2 level [34]. The expanding work
on CCC influence on neuronal excitability in physiological conditions especially during
development and pathological conditions suggest that they could be a new treatment
approach for stroke [27].
In view of this, constant updates on the role of CCCs in stroke and their regulation
is highly germane for the development of therapeutic drugs in the management of this
pathology. Thus, the aim of this review is to summarize the current understanding of
functional regulation of the CCCs and particularly the role of NKCC1 and KCC3 cotrans-
porters in the pathogenesis of stroke. Then, the regulatory role of the with-no-lysine kinase
(WNKs) family and STE20/SPS1-related proline/alanine rich kinase (SPAK) or oxidative
stress response kinase (OSR1) (WNK-SPAK/OSR1) signaling pathway in stroke will be
considered. Lastly, current pharmacological treatments for stroke with respect to potent
inhibitors of WNK-SPAK/OSR1 pathway and NKCC1 cotransporter, and activators of
KCC3 transporter will be discussed in this review.
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Table 1. The solute carrier family 12 (SLC12) of cation-chloride cotransporters in neurological disorders and others. TAL:
thick ascending loop of Henle; DCT: distal convoluted tubule; RVI: regulatory volume increase; RVD: regulatory volume
decrease; ND: no data (or none). Functional regulation of the cation-chloride cotransporter family.
Encoding Gene
(Protein) Co-Transport Ions Tissue Distribution Physiological Functions Genetic Disorders References
SLC12A1 (NKCC2) Na+, K+, Cl− Kidney-specific(TAL)
NaCl reabsorption in the




SLC12A2 (NKCC1) Na+, K+, Cl− Ubiquitous
Cell volume regulation
(RVI); provide ions for
secretion








SLC12A3 (NCC) Na+, Cl− Kidney-specific(DCT)
NaCl reabsorption in the
DCT; regulation of Ca2+
and K+ renal excretion;
Gitelman’s syndrome [9,44,45]














SLC12A6 (KCC3) K+, Cl− Widespread
Volume regulation in the













SLC12A8 (CCC9) Unknown Widespread No function ascribed yet Psoriasis, dyslipidemia [2,16,17,58,59]
SLC12A9 (CIP) Unknown Widespread No function ascribed yet




Undoubtedly, for a cell to function properly it is essential to maintain constant intra-
cellular ionic milieu [53]. Homeostasis of [Cl−]i in particular, influences the movement of
fluid across epithelia, the polarity of GABA, and more. The electroneutral CCCs are critical
determinants of [Cl−]i [53,60]. The [Cl−]i gradient across the neuronal membrane is crucial
for controlling the polarity of GABAergic signaling. GABAA conducts Cl− ions. The di-
rection of Cl− movement through GABAA, which determines whether it is excitatory or
inhibitory, is dependent on the [Cl−]i gradient. Entry of Cl− through GABAA results in the
hyperpolarization of neurons and the extrusions of Cl− through GABAA depolarizes the
neurons [23,61–63]. Changes in expression levels of the CCCs during development reverses
the chloride gradient in neurons, generating a switch from an excitatory GABA to an in-
hibitory GABA [23,64]. NKCCs facilitate Cl− movement into the cell, while KCCs facilitates
Cl− movement out of the cell. Thus, NKCCs promote an increased participation of [Cl−]i
in the pathways for regulatory volume increase (RVI), while the KCCs promote decrease in
the [Cl−]i as one of the regulatory volume decrease (RVD) mechanisms [19,53,65] (Figure 1).
These evolutionarily conserved transporters are amongst the most important mediators of
ion transport in multicellular organisms, with particular importance in mammalian central
nervous system (CNS) regulation of ionic and water homeostasis [66]. As mentioned ear-
lier, the CCCs are involved in several important cellular functions such as trans-epithelial
ion transport, cell volume regulation, and maintenance of [Cl−]i. Their importance in
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physiological function is evident by the many human Mendelian disorders of the brain
and renal phenotype that arise due to mutations in some members of the CCC family and
their upstream regulators [19] (Table 1). For instance, reduction in neuronal KCC2 activity
results in decreased inhibition and a hyper-excitable network, a feature shared amongst
numerous neurological disorders including epilepsy, autism, post-surgical complication,
neuropathic pain, and neuropsychiatric disorders [48,53,67,68].
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Since CCCs are key players in several important cellular functions and principally
responsible for reciprocal cations (Na+ and K+) exchange with Cl− to maintain cellular
bal nce, regulatory mechanisms are crucial to coordi ate their activity [53,60,67,69]. Indeed,
several kinases a d phosphatases regulate their transport activity. However, previous
reports have established that members of the WNKs family and their downstream targets,
SPAK and OSR1, are the master regulators of CCCs activity [1,53,60,65,70–75].
Though it has been appreciated for some three decades that protein phosphorylation
coupled with external osmotic environment are crucial components in regulation of CCC ac-
tivities [2,54,76–80], knowledge on the enzymes that regulate these signaling networks was
sparse then. The WNK family encoded by the genes WNK1–4 [81], SPAK, and OSR1 play
crucial roles in the regulation of cell volume homeostasis through the regulation of intracel-
lular Na+, K+, and Cl− [53,82]. The many roles of the WNK-SPAK/OSR1-CCC pathway
which include cell volume homeostasis, epithelial transport, and GABA signaling are asso-
ciated with an array of pathologies which include essential hypertension, cerebral edema,
anemia, and neuropathic pain [1,19,53,60,65,67,71,73]. In response to osmotic stress of low
[Cl−]i, isoforms of WNK are activated through phosphorylation. The WNK isoforms then
phosphorylate the related downstream kinases SPAK and/or OSR1 [83,84]. Activated SPAK
and/or OSR1 phosphorylates the CCCs, which activates NCC, NKCC1, and NKCC2 but
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inhibits KCCs through a reciprocal regulatory mechanism [67,72] (Figure 2). The counter
regulation of the CCCs coordinates Cl− movement across the membrane to maintain Cl−
homeostasis and circumvent superfluous energy utilization [65].
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by inhibiting Table 1 kinases. Reversible serine-threonine phosphorylation reciprocally regulates NKCC1 and KCC3.
Hypotonic low [Cl−]i conditions or a reduction in cell volume activates the WNK-SPAK/OSR1 pathway to promote Cl−
and water influx. T is leads to the phosphorylation of NK C1 and KCC3 and their activat on and inhibition respectively.
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specific SPAK inhibitor. Part of figure elements were adapted from Salihu et al. [85].
To maintain cell volume homeostasis, the WNK-SPAK/OSR1 kinase pathway activates
NKCC1 and simultaneously inhibits KCCs through phosphorylation. Conversely, dephos-
phorylation inhibits NKCC1 and activates the KCCs [86]. The major phosphorylation sites
of NKCC1 include Thr203, Thr207, and Thr212 in the N-terminus whilst the phosphorylation
sites of KCC1–4 are located in the C-terminus (Thr991 and Thr1048 in KCC3 and Thr906 and
Thr1007 in KCC2) [59,72]. Notably, the phosphorylation sites on KCC3, Thr991 and Thr1048,
are conserved amongst all KCC isoforms in humans [72]. Substitution of these threonine
residues that make up the sites of regulated phosphorylation inhibited the phosphorylation
and subsequent activation of KCC2 a d KC 3 [86–88]. Recently, it was established that the
WNK3-SPAK complex is critical for regulated phosphorylation of KCC3 Thr991 and Thr1048
residues [86] (also ee Figures 3 and 4).
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KCC3. OSR1 lack the P/A rich (PAPA) domain that is present in SPAK. The figure depicts small
molecule inhibitors that target the WNK-SPAK-CCC signaling pathway and their sites of actions.
STOCK1S-50699 and STOCK2S-26016 operate through binding to the CCT domain consequently
blocking the interaction between SPAK/OSR1 and WNK. STOCK1S-14279, Closantel, Rafoxanide,
Verteporfin, and 20l bind the T233E residue on SPAK that is constitutively active or WNK-sensitive.
WNK463 and PP121 that inhibit WNKs catalytic activity. HK01, an inhibitor of the mouse protein-
25 (M025). Bumetanide, ARN23746 and STS66 are NKCC1 antagonists. Furosemide is a KCC3
inhibitor. ZT-1a is a specific SPAK inhibitor. CCCs, cation-chloride cotransporters; NKCC1, K+-Cl−
cotransporters; KCC3, K+-Cl− cotransporter 3; WNK, with-no-lysine kinase; SPAK, STE20/SPS1-
related proline/alanine rich kinase; OSR1, oxidative stress response kinase.
Specific conserved carboxyl-terminal (CCT) domains on SPAK/OSR1 interact with
NKCC1 and KCCs [80,86,89]. The Arg-Phe-Xaa-Val/Ile (RFXV/I) domain located in the N-
terminal of NKCCs and KCCs is able to recognize the SPAK CCT domain (Figures 3 and 4).
Interestingly, a subtype of the KCC2 isoform, KCC2b lacks the RFXV/I motif to facilitate
interaction with SPAK. Thus, only KCC2a transport activity decreased when SPAK was
overexpressed [53,90]. This interaction of SPAK/OSR1 with both the upstream WNKs
and downstream CCCs is crucial for coordinating CCC cellular activity in various osmotic
conditions [89,91]. The binding of WNK to SPAK/OSR1 allows for the phosphorylation of
residues in the T-loop of the SPAK catalytic domain required for SPAK activation [89,91].
Only once activated is SPAK then able to phosphorylate and inhibit KCC2 and KCC3
at Thr1048 and Thr1007 respectively and activate NKCC1 at Thr203/Thr207/Thr212. These
processes are essential in response to cellular shrinkage and hypertonicity (Figure 1) [53].
In hypertonic conditions, SPAK/OSR1 phosphorylation and activation of NKCC1 is key
to achieve RVI [53,67] as an influx of Na+, K+, Cl− through the NKCC1 along with water
will allow for cell volume recovery (Figure 1). Under hypotonic extracellular conditions,
water enters the cells and causes cell swelling, subsequently triggering a counter-volume
regulation response (RVD). The WNK-SPAK/OSR1 pathway in this condition remains
inactive and inhibits NKCC1 activity (Figure 1). Furthermore, the dephosphorylation of
KCCs mediated by phosphatase stimulates KCC activity and causes efflux of K+ and Cl−
along with water, decreasing cell volume (Figure 1) [65]. Thus, pharmacological or genetic
antagonistic events of WNK-SPAK/OSR1 will lead to a [Cl−]i efflux coupled through
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simultaneous dephosphorylation of NKCC1 and KCCs. This will then mitigate energy
failure occasioned by osmotic stress, as evident in some neurological disturbances such as
cerebral edema [32,65,67,86,92].
2. Role of NNKCC1 in Stroke
NKCCs play crucial roles in regulating neuronal functions. They are abundantly ex-
pressed in neurons throughout the brain and are involved in ion homeostasis maintenance
and neuronal excitatory functions [93]. Majorly, they function in regulation and repair
of nerve injury through GABAergic signaling [1,94]. However, under specific conditions
such as cerebral ischemia, the expression of NKCCs can be altered [94]. Overstimula-
tion of NKCC1 and other major glial ion transporters (such as Na+/H+, Na+/Ca2+ and
Na+/HCO3− exchangers) can contribute to glial apoptosis, inflammation, demyelination,
inflammation, and excitotoxicity [26]. This cascade of events is involved in the development
and progression of neurological diseases such as stroke [26]. Studies have demonstrated
evidence of increase NKCC1 expression in neurons, a phenotype resembling immature
neurons, following an ischemic stroke [95–97]. The altered NKCC1 expression observed
post stroke may be responsible for the increased in Na+ and Cl− levels in neurons leading to
a GABA-mediated depolarization. These events also contribute to a hyper-excitable neuron
and cell swelling occasioned by cerebral ischemia [95,98]. Furthermore, disrupted endo-
plasmic reticulum Ca2+ homeostasis [99] and elevated extracellular levels of potassium,
glutamate, interleukin-6 [100], interleukin-18 [101], interleukin 1β, and tumor necrotic
factor-α [102] which happen during/post cerebral ischemia have been shown to stimulate
NKCC1 mRNA gene expression in both neurons and astrocytes. Notably, the elevated
extracellular potassium levels seems to be Ca2+-dependent as NKCC1 activation is com-
pletely terminated either through the removal of extracellular calcium or using Nifedipine
to block L-type voltage-dependent calcium channels [103]. Comparatively, similar effects
were seen in the expression of NKCC1 mRNA gene in white and gray matter of mutant
and wild-type (WT) mice [104]. In addition, [105] an epigenetic study using quantitative
real-time RT-PCR technique on cortical slice culture from rats suggested that DNA methy-
lation/demethylation contribute to the regulation of NKCC1 expression during postnatal
development and in response to neuronal injury (ischemia) [105].
Following ischemic stroke, both NKCC1 and KCCs are phosphorylated via the WNK-
SPAK/OSR1 signaling pathway, leading to NKCC1 activation and KCC inhibition [22,65].
Other contributors leading to NKCC1 activation following an ischemia include: the WNK-
calcium binding protein (Cab39; [106]) as well as antagonists of V1 vasopressin [107],
MAPK (p38, ERK, JNK, Raf) pathways, cAMP response element-binding protein (CREB)
phosphorylation and the ubiquitous transcription factor; hypoxia inducible factor 1-alpha
(HIF-1α). This leads to the stimulation of vascular endothelial growth factor (VEGF) expres-
sion and ultimate onset of ischemic stroke [37,108–110]. Studies on the human subacute
ischemic stroke brain tissues demonstrate increased NKCC1 mRNA gene expression [106].
The contribution of NKCC1 protein activation to ischemic brain havocs is now evident as
genetic deletion of NKCC1 or its upstream regulator WNK3 in mouse transient middle
cerebral artery (MCA) occlusion models displayed minimal infarction, edema, and white
matter damage [32,104]. Another study demonstrated increased NKCC1 activity in the
perilesional cortex of rats challenged with focal cerebral ischemia induced by endothelin-1
(ET-1) [111]. Furthermore, inhibition of NKCC1 has been reported to reduce edema, Na+
uptake, and ischemic injury in rats subjected to STZ-induced hyperglycemic ischemic
stroke [112].
3. Role of KCC3 in Stroke
Here, we recall as stated earlier in Section 2 of this review that the stimulation/inhibition
of NKCCs/KCCs pair via protein phosphorylation is through a reciprocal regulatory mech-
anism [67,72] (Figure 2). NKCC and KCC participations in cell volume regulations via RVI
and RVD mechanisms, respectively, have also been earlier highlighted [19,53,65] (Figure 1).
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It is only expected that in neuronal functions regulation, activation of KCC3 would play
similar physiological roles to those that the inhibition of NKCC1 would. The WNK-Cab39
signaling increased expression of NKCC1 mRNA gene in brain tissues of rats subjected
to ischemic stroke. It is proposed to have probable effects on the expression of other
cotransporters such as KCC3 [106]. KCC3 expression in the brain requires NKCC1 ex-
pression for physiological regulation of cellular homeostasis in the CNS [72,86,87,113,114].
Hence, the roles of WNK-Cab39-KCC signalling in ischemic stroke should be further
investigated [106]. In a mouse model study, Lucas et al. [114] demonstrated that along-
side inhibited NKCC1, stimulation of KCC3 promoted decreased [Cl−]i in the sensory
neuron of adult mice. This suggests their involvement in GABAergic/glycinergic trans-
mission as adjudged by its influence on the hyperpolarization of GABAA equilibrium
potential (EGABA-A) resulting in inhibitory GABAergic neurotransmission due to a decrease
in [Cl−]i. Our recent functional kinomics study alluded that regulatory phosphorylation of
KCC3 (Thr991/Thr1048 residues) is essential for cell volume homeostasis in the mammalian
brain [86]. The notion that supports KCC3 physiological role in regulating [Cl−]i and
consequent influence on GABA polarization state is fascinating and suggests possible
relationship between neuronal excitability and cell volume homeostasis [86]. Moreover,
this concept behind the physiological function of KCC3 is an indication that it might have a
dual role in the regulation of both cell volume and [Cl−]i [66] which will be highly relevant
in understanding its role in the etiology of stroke.
Furthermore, Byun and Delpire [115] reported that stimulation of KCC3 are involved
in cell volume regulation (via RVD) in the nervous system, thereby emphasizing its role
in the development and maintenance of myelin and peripheral nerves. The study further
established that inhibition of KCC3 by knocking out its expression in mice caused anoxal
and periaxonal swelling that ultimately led to neurodegeneration [115]. Another mouse-
model study demonstrated that KCC3 gene knockout (KO) in parvalbumin neuron caused
peripheral agenesis neuropathy associated with the agenesis of corpus callosum. Similarly,
the post-mortem study by Auer and colleagues [116] suggested that neuropathological
features observed in the central and peripheral nervous systems (CNS/PNS) could poten-
tially link to genetic defects in axonal KCC3 of CNS/PNS. Indeed, sensory defects in KCC3
knockout (KCC3−/−) mice as well as its mutations in humans [63,66,117–119] confirm the
fundamental role of the cotransporter in peripheral neurons (also see reviews [53,65,66]).
Loss of function mutations function of KCC3 have contributed to the pathogenesis of
motor and sensory peripheral neuropathy in adult animals and humans [114,115,120–122].
Manifestations of peripheral neuropathy or fluid-related axonopathy influence cell volume
dysregulation [26,115] and may be involved in the pathogenesis of other neurological
conditions such as stroke.
4. Role of Regulatory WNK-SPAK/OSR1 Pathway in Stroke
Certainly, the various cellular functional roles of CCCs in the biological system will
be compromised without regulatory mechanisms in place. Thus, it is only principally
reasonable that the cotransporters actively and continuously maintain their functional
integrity through coordinated mechanisms of regulations [53,60,67,69]. Several reports
owing to WNK-SPAK/OSR1 kinases as the most involved signaling pathway in the reg-
ulation of neuronal Cl− and cell volume homeostasis do exist [60,65,70,71,123] and these
established roles of the WNK-SPAK/OSR1-CCC pathway have alluded to their connection
with stroke [19,65,71].
There is a growing body of evidence that the WNK-SPAK/OSR1-CCC pathway is
involved in pathogenesis of stroke [53,65,70,106,124]. The established roles of the WNK-
SPAK-CCC pathway on GABA signaling and cell volume homeostasis are linked to several
neurological diseases such as cerebral stroke [53,60,125]. WNK and SPAK/OSR1 kinases
are copiously expressed in the CNS [75]. After an ischemic stroke, both NKCC1 and KCCs
are phosphorylated via the WNK-SPAK/OSR1 signaling pathway, leading to activation
and inhibition of NKCC1 and KCCs, respectively [22,65]. However, inactivating the WNK-
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SPAK-CCC cascade through concurrent inhibition of NKCC-mediated ionic influx and
stimulation of the KCC-mediated ion efflux has been shown to reduce cellular swelling in
ischemic stroke brains [53,65]. The regulatory role of WNK-SPAK-CCC in cellular ionic
homeostasis have also been shown to contribute to post-ischemic stroke infarction and
cerebral edema [66]. Thus, inactivation of the WNK-SPAK-CCC cascade would trigger the
simultaneous inhibition of NKCC mediated ionic import and stimulation of KCC mediated
ionic export to eradicate cellular osmotic imbalance [53,65]. It has also been reported that
estradiol increases NKCC1 phosphorylation consequently promoting GABA-mediated
depolarization [126]. This occurs through stimulation of SPAK and OSR1 that is transcrip-
tion dependent [127]. Studies using focal ischemia rat model have shown that estradiol
treatment promotes neurogenesis in the subventricular zone of the brain, probably by in-
creased expression of HIF-1α and VEGF [128]. WNK phosphorylate SPAK/OSR1, which in
turn, phosphorylate NKCC1 and KCC3 at key regulatory sites [129]. Previous reports have
shown that SPAK has a CCT domain to interact with NKCC1 and the KCCs [11,89,91,130].
However, the understanding of their physiological functions in normal and ischemic brains
are still elusive [92].
Indeed, WNK isoforms are selectively expressed in the CNS [131] and WNK3 is mostly
expressed in the brain [132]. This particular WNK isoform exerts its action on NKCCs and
KCCs reciprocally [53,113]. Thus, the reciprocal actions of WNK3 on NKCC1 and the KCCs
along with its concurrent expression with cotransporters in GABAergic neurotransmission
that undergo dynamic changes in [Cl−]i, suggest its involvement in regulation of neuronal
CCCs [53,133,134]. In fact, Kahle et al. [113] provided a compendium of data that suggested
WNK3 as a dynamic regulator of NKCC1 and KCCs physiological activities. Simultaneous
expression of WNK3 and NKCC1 in neurons may lead to enhanced phosphorylation of
regulatory sites in NKCC1 and a consequent increase in the activity of NKCC1 [32,135].
The target of protein phosphatase 1 (which recognizes the consensus motif: RVNFXD) is
a highly conserved RVNFVD sequence that is located in the amino-terminus of NKCC1.
The RVNF binding motif overlaps with the SPAK binding motif (RFRV). A slight mutation
of this sequence will cause NKCC1 activity to increase [136]. Interestingly, phenotypes
of NKCC1 inhibition and KCC activation due to inactive WNK3 signaling pathway are
reversed by potential protein phosphatase 1 inhibitors such as calyculin A and cyclosporine
A [133,137]. According to Melo et al. [138], WNK3 inhibits the activity of KCC3 by pro-
moting the phosphorylation of Thr991 and Thr1048 as well as Ser96, a third phospho-site
involved in KCC3 regulation (also see Figure 2). Double (KCC3-T991A/T1048A) or triple
(KCC3-S96A/T991A/T1048A) alanine mutations of KCC3, activated the cotransporter,
which further increased hypotonicity. Thus, the study suggested that the phosphoryla-
tion of WNK3 signaling pathway was disabled, subsequently activating KCC3 by cell
swelling [138].
Certainly, the upstream WNK3-SPAK/OSR1 pathway regulation of NKCC1 activity
coupled with inhibition of KCC3 is implicated in the pathology of ischemic stroke [86].
Previous studies have demonstrated that WNK3 KO mice exhibited a reduction in in-
farct volume and axonal demyelination coupled with diminished cerebral edema and
improved neurological behaviors following cerebral stroke when compared to WT mice
with significantly activated WNK3 [32,86,92]. However, it is important to note that WT
mice showed better survival and functional outcomes after a brain edema in compari-
son to mouse models lacking aquaporin-4 (AQP4) [139], a water transport system that
allows for bidirectional water flux. As such, further research will need to elucidate the
distinction between the role of AQP4 and WNK3 in cerebral edema and stroke. Thus,
Begum and colleagues [32] observed stimulation of WNK3 and SPAK kinases in corti-
cal neurons and primary oligodendrocytes cultured from the brain of mice subjected to
transient MCA stroke [32]. They further established that cerebral ischemia facilitates hyper-
phosphorylation of the WNK3-SPAK/OSR1 catalytic T-loop and of NKCC1 stimulatory
sites (Thr203/Thr207/Thr212); thus, increased expression of NKCC1 in the brain cells [32].
However, transgenic KO of WNK3, abridged ischemia-mediated SPAK/OSR1-NKCC1
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phosphorylation and displayed reduced cerebral edema, axonal demyelination, and infarct
volume, as well as improved post-stroke neurological recovery when compared to WT
mice [32]. Briefly, the data presented by Begum et al. [32] identify the role of WNK3-
SPAK/OSR1-NKCC1 signaling pathway in ischemic neuroglial injury and suggested that
obstruction of this pathway could reduce NKCC1 expression in the brain and avert post-
stroke neuronal cell death following [32]. Similarly, Zhao et al. [92] demonstrated that KO
of the WNK3-SPAK kinase complex in mice instigates decreased expression of NKCC1
and subsequently ameliorated cerebral infarction and edema after MCA stroke. Gener-
ally, deletion of the WNK3-SPAK kinase complex significantly produced less cytotoxic
edema, less demyelination, and improved post-ischemic stroke neurological outcomes in
the transgenic mice [92]. However, it is worth noting that the mechanism(s) of regulations
employed by WNK3-SPAK/OSR1-NKCC1 signaling pathway in oligodendrogenesis is
still elusive and requires further studies [26]. In addition, we recently demonstrated that
WNK3 KO mice exhibit reduced endothelial and perivascular cytotoxic edema of astrocytes
following post-ischemic stroke [86]. We further alluded that WNK3-SPAK inhibition confer
neuroprotection on mammalian brain through concurrent stimulation of KCC3 activity at
Thr991 and Thr1048 residues and inhibition of NKCC1 activity at Thr203, Thr207, and Thr212
residues [86].
In a recent rat model study, Bhuiyan et al. [106] demonstrated that WNK-Cab39-
NKCC1 signaling pathway is implicated in ischemia. Furthermore, they suggested that
activated WNK-Cab39 pathway increased NKCC1 activity in brain tissues of spontaneous
hypertensive rats following subacute ischemic stroke [106]. A more recent similar report
by Huang et al. [124] demonstrated that ischemic stroke with hypertension comorbidity
further stimulates the WNK-SPAK/OSR1-NKCC1 signaling pathway, which contributes
to deteriorated neurological functions/behavior [124]. In fact, the established role of
WNK-SPAK/OSR1 signaling pathway in stimulating NKCC1 and inhibiting KCC3, which
contribute to the pathogenesis of stroke, are the reasons for our recent pharmacological
studies [70,71].
5. Current Pharmacological Treatments for Stroke
We underscored in the earliest section of this review that stroke is one of the major
threats to global health. Over the years, stroke had been a chief contributor to mortality and
disabled lives across the globe; there are projections that the impact of this disease on global
health may be worse in the near future. Presently, there are only few pharmacological
strategies available to reduce the health and socio-economic burden triggered by this
disease. Thus, there is an urgent need to tackle this disease. In this regard, research on the
role of CCCs in the pathogenesis of stroke to inform future drug development is needed.
Accordingly, this section of the review highlights current pharmacological approaches in
the management of stroke with particular focus on molecular compounds that potentially
inhibit SPAK/OSR1 pathway and NKCC1 and stimulate KCC3.
5.1. Inhibitors of WNK-SPAK/OSR1 Pathway
A quick recap of the following crucial information from previous sections, which may
contain pharmacological strategies for managing stroke: (1) WNK-SPAK/OSR1 modulates the
activities of CCCs through a well-coordinated reciprocal pattern of regulation [53,60,67,69],
(2) activation of WNK-SPAK/OSR1 signaling pathway stimulates NKCC1 and inhibits
KCC3 expressions [19,53,67,72], and (3) development and progression of stroke have been
implicated with phosphorylated WNK-SPAK/OSR1 signaling pathway and subsequent up-
and down-regulations of NKCC1 and KCC3 expressions, respectively [22,140]. Therefore,
we can safely presume that molecular compounds that act as pharmacological or genetic
antagonists of WNK-SPAK/OSR1 kinases are likely potential drug candidates for the
treatment of stroke. Recent reports have shown that drugs that are potent blockers of WNK-
SPAK/OSR1 signaling pathway reduce phosphorylation of NKCC1 and KCC1 which
enables cellular chloride expulsion, subsequently mitigating cerebral edema and other
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neurological anomalies following ischemia. This then protects against brain damage and
enhances post-stroke brain functions [32,65,70,86,92,94,124,141].
The WNK-SPAK/OSR1 pathway constitutes potential therapeutic targets in Cl−
dysregulation [23]. The loop diuretic, bumetanide protects the brain from damage by medi-
ating GABAergic signaling in NKCC1 expression following ischemic injury [22,23,26,142].
Furthermore, treatment with the drug reversed the impact of GABA-mediated depolariza-
tion, which may promote functional recovery after stroke via neuron repair/protection
as adjudged by its effect of GABAA receptor antagonist and WNK3 knockout [94,142].
Pharmacologically targeting the WNK-SPAK/OSR1 kinase pathway could be a strategy
to restore GABAergic inhibition [23]. Indeed, genetic or pharmacological inhibition of
WNK-SPAK/OSR1 activity would lead to cotransporter dephosphorylation: inhibition of
NKCC1 and activation KCC3, which would enhance [Cl−]i extrusion [67]. Furthermore,
enhancement of [Cl−]i extrusion in the neurons would facilitate GABAA receptor-mediated
hyperpolarization and thus inhibit neuronal activity through combined NKCC1 inhibition
and KCC3 stimulation [19,22,53,65,67] (Figure 2).
Recent studies have indicated that decline in NKCC1 protein expression along with
WNK3 knockdown, contributes to lessened post-stroke brain injury and accelerated neu-
robehavioral recovery [32,86,92]. These reports and more have immensely motivated
the development of novel therapeutic strategies that have targeted WNK-SPAK/OSR1
signaling pathways to improve post-stroke physiological functions [70,106,124]. A recent
rat model study demonstrated an upregulation of WNK-SPAK/OSR1-NKCC1 signaling
pathway in the brains of spontaneously induced-hypertensive rats and subsequently aug-
mented susceptibility to ischemic damage [106]. However, intraperitoneal administration
of bumetanide (10 mg/kg) post-reperfusion blocked the WNK-Cab39-NKCC1 signaling
pathway and subsequently mitigated post-ischemic infarction and cell swelling and im-
proved neurological functions in animals [106]. Loop diuretics are often used to inhibit
NKCCs. Inhibition of NKCC2 promote diuresis in the kidney and reduces pressure due to
excess fluid in the lungs. Hence, loop diuretics are a treatment option hypertension and
pulmonary edema. Although some loop diuretics inhibit KCCs, they do so very poorly.
Researchers have explored the loop diuretics bumetanide and furosemide as novel treat-
ment options for brain disorders [65]. However, a number of unfavorable physiochemical
characteristics associated with the use of bumetanide [23,41,65] call for better alternatives
in the management of neurological diseases including stroke. Recently, Huang and co-
workers [124] reported that a novel NKCC1 inhibitor (STS66) is superior to bumetanide
in ameliorating ischemic brain injury following transient MCA occlusion and large-vessel
ischemic stroke models. In the study, ischemic injury stimulated WNK-SPAK-NKCC1
cascades in brains of AngiotensinII (AngII)-induced hypertensive mice. However, STS66
treatment completely blocked this pathway and by implication mitigated ischemic infarc-
tion, cerebral edema, and neuronal death as well as neurological deficits in both stroke
models with hypertension comorbidity [124].
We recently proposed that improved understanding of cooperative interactions among
different phospho-sites of cotransporters and the molecular mechanisms involved in their
physiological regulations could provide insights to inform potential pharmacological inter-
ventions [71]. Recently, we conducted a large-scale phospho-proteomics study with the
application of immunoblot and phospho-antibodies immunoprecipitation techniques to
investigate the regulatory mechanisms of a broad kinase inhibitor, staurosporine and N-
ethylmalemide (NEM), a modulator of both kinase and phosphatase activities on phospho-
rylation of specific KCC2 and NKCC1 in HEK293 cells and immature cultured hippocampal
neurons [71]. Our analyses revealed dephosphorylation of Thr203, Thr207, and Thr212 of
NKCC1 and Thr1007 of KCC2 following application of the two agents. The two compounds
resulted in dephosphorylation of sites Thr233 and Ser373, phosphorylation sites located
within the T-loop and S-loop of SPAK. Hence, the study suggests the inhibitory effect of
staurosporine and NEM on WNK-SPAK/OSR1 signaling pathway in the regulation of
NKCC1 and KCC2 is in a reciprocal pattern [71]. We are of the opinion that the underlying
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information from this study will be highly important for future development of integrative
therapeutic strategies in the management of neurological diseases such as cerebral stroke.
Importantly, evolving roles of WNK-SPAK/OSR1 signaling in stroke as discussed in
this review, points to additional possible applications of WNK-SPAK/OSR1 modulation in
neurological diseases. In view of this, a promising strategy could involve exploitation of
the unique structure of these kinases to enhance protein specificity [53,70]. Immense efforts
to inhibit WNKs or SPAK/OSR1 for the treatment of human diseases such as hypertension
have led to the discoveries of small molecule inhibitors. WNK kinase inhibitors include
WNK463 [143], PP121 [144], and SPAK inhibitors such as STOCK1S-14279, Closantel [145],
Rafoxanide [146], Verteporfin [74], STOCK1S-50699, and STOCK2S-26016, [147], as well
as HK01 [148] and 20I [149] (also see Figures 3 and 4). Unfortunately, none of these
compounds is an ideal drug candidate for the treatment of brain disorders due to their
relatively low penetrability through the blood-brain barrier (BBB). Recently, we employed
a scaffold-hybrid strategy in our laboratory to develop a novel compound ZT-1a. ZT-1a is
a non-ATP-competitive SPAK blocker, which specifically inhibits this signaling pathway by
decreasing SPAK-dependent phosphorylation of NKCC1 and KCCs in cell cultures as well
as in vivo mouse and rat brains [70]. In brief, treatment with ZT-1a (2.5–5.0 mg/kg) abated
post-stroke related brain injuries and improved neurological features/functions. The data
from the study suggests that ZT-1a or related compounds that are CCC modulators could be
a therapeutic strategy for neurodegenerative disorders such as cerebral stroke [70]. Hence,
we holistically advocate for follow-up with detailed research studies on the development of
more WNK-SPAK/OSR1 inhibitors with favorable pharmacokinetic properties for clinical
use.
5.2. Inhibitors of NKCC1
It has been established that the recovery process from many neurological disorders
including stroke would highly benefit from inhibition of NKCC1 activity [94]. Suppres-
sion of NKCC1 activity through bumetanide is neuroprotective and improves post-stroke
neurophysiological status [142,150]. Thus, bumetanide has the potential to influence many
CNS disorders [94]. Several studies have demonstrated the contribution of NKCC1 in
the development and progression of post-stroke edema and cell death, thus targeting
NKCC1 could be a potential neuroprotective target [22,26,32,65,111,151]. In fact, a phar-
macological study using bumetanide demonstrated a significantly reduced neuronal Na+
overload and cell death. Bumetanide also simultaneously reduced infarct volume and
brain edema [104]. Another rat model study showed that bumetanide administered after
focal cerebral ischemia in rats (given 7 days post-ischemia, and continued for 21 days),
improved behavioral recovery and promoted neurogenesis 4 weeks post-havoc [141]. Low
concentrations of bumetanide (2 to 10 µM) are capable of inhibiting NKCCs in vitro with
no significant effect on the KCCs; a high concentration has been shown to inhibit the
activities of both NKCC1 and KCC2 [152,153]. The expression of NKCC1 is common at the
luminal side of endothelial cells of the BBB, thereby allowing easy interaction between the
transporter and its inhibitor (bumetanide) when administered intravenously, which subse-
quently decreased edema in MCA occlusion model of stroke in rats [154]. Bumetanide acts
through docking to the binding site at the trans-membrane region of NKCC1. Docking to
this region allows for the inhibition of NKCC1 activity and reduced [Cl−]i in neurons [94];
a more likely mechanism through which the drug confers neuroprotection and neuronal
recovery following stroke episodes [94,155].
Simard et al. [156] and Walcott et al. [42] in their respective reviews highlighted
the implication of the constitutive expression of NKCC1 and SUR1-regulated NCCa-ATP
(SUR1/TRPM4) channel on the cascade of events that are involved in the pathogenesis
of cerebral ischemia and the impact of combinatorial therapy of bumetanide and gliben-
clamide in ameliorating the havoc. Bhuiyan and colleagues [106] reported that bumetanide
downregulated the WNK-Cab39-NKCC1 signaling pathway, consequently reducing the
susceptibility of hypertensive rats to ischemic brain damage. Furthermore, in a recent
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study a synergistic treatment with mild hypothermia (33.5 ◦C for 30 min) and inhibitor
DAPT (50 µM) attenuated the overexpression of NKCC1 mRNA following global cerebral
ischemia injury in rats [20].
In animal stroke models, bumetanide administration pre- and post-stroke induction
led to the down-regulation of NKCC1 expression. Other observations include a reduc-
tion in edema, infarction volume, and ischemic necrotic cell death especially in the early
stage of ischemic damage, promotion of neurogenesis, and improved sensorimotor re-
covery [17,97,109,141,157,158]. In another rat model study, ET-1 was used to induce focal
ischemia but post treatment with bumetanide selectively inhibited NKCC1 expression in
the cortex and promoted synaptic plasticity in the denervated cervical spinal cord following
cerebral ischemia [111]. Similarly, Xu et al. [141] demonstrated that chronic treatment with
bumetanide promotes neurogenesis and behavioral recovery after ET-1-induced stroke
in rats. In addition, bumetanide (10 µM) was used in another study to block NKCC1 in
order to facilitate decreased [Cl−]i in hippocampal tissue cultured from rats either during
oxygen-glucose deprivation for 120 min or post-exposure. The drug improved neuronal vi-
ability during the acute ischemic episode which suggested its critical role in the modulation
of transmembrane chloride transport [27].
Indeed, bumetanide appears to be a promising pharmacological inhibitor of NKCC1;
it possess some demerits that may limit its application as an anti-stroke drug to some
extent [23,94]. Alongside bumetanide, a novel inhibitor STS66 (a prodrug of bumetanide)
also exhibits promising potential as a pharmacological inhibition of NKCC1 and has been
demonstrated to also reduced ischemic infarction, swelling and neurological deficits in mice
model of transient ischemic stroke [124]. Interestingly, STS66 can penetrate BBB more easily
and appears to be more efficient in eliciting the aforementioned anti-stroke properties [124],
which is one of the various reasons it has been recently proposed as a better therapeutic
drug in stroke management when compared with bumetanide [23,65]. A finding contrary
to the common hypothesis on the efficacy of bumetanide was recently reported [18]. In this
study, post treatment with bumetanide (40 mg/kg) following Intracerebral hemorrhage
induction in male Sprague Dawley rats failed to improve behavior or lessen injury neither
did the drug normalized ion concentrations after late dosing [18].
In spite of the positive outcomes demonstrated clinically by administration of bumetanide
to patients with psychiatric/neurological conditions [159–166]; the drug has exhibited
strong diuretic effect resulting from the inhibition of NKCC2 expression in the kidney which
may pose serious challenges to issues on drug compliance and health concerns [167–169],
thereby limiting the therapeutic applications of bumetanide. Hence, selective inhibition
of NKCC1 in lieu of renal NKCC2 may attenuate the diuretic glitches. In this regard,
Savardi et al. [170] recently discovered ARN23746, a selective inhibitor of NKCC1 in lieu
of NKCC2 and KCC2 in vivo. The reports from the study demonstrated that the pharma-
cokinetic profile of ARN23746 is better when compared with that of bumetanide in vitro
and in vivo. Briefly, the study demonstrated that ARN23746 (10 µM) restored aberrantly
high [Cl−]i to the physiological level in mature hippocampal neuronal cultures of Ts65Dn
mouse model Down syndrome (DS) coupled with rescued cognitive impairment in Ts65Dn
with no significant diuretic effect in either the WT or Ts65Dn mice [170]. Furthermore,
the researchers demonstrated that intraperitoneal administration of ARN23746 recovered
social and repetitive behaviors associated with the main symptoms of autism spectrum
disorder (ASD) in valproic acid (VPA) mouse model of ASD. In addition, neither diuretic
effect nor overt toxicity of the compound were present in the ARN23746 treated mice [170].
ARN23746 has great potential for further development into a clinically-relevant drug
for the treatment of DS, ASD [170], and possibly several other neurological conditions
characterized by impaired Cl− homeostasis including stroke.
5.3. Activator of KCC3
The KCCs, especially KCC2 and KCC3, are popular due to increased findings on
human disease-causing mutations [68,121,122]. Hence, the discovery of small molecules
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that modulate these cotransporters’ activities is prioritized within the field. Discovery of
such modulators may aid development of therapeutic drugs for the management of KCC-
related diseases as well as other pathological conditions including stroke [171]. Currently,
the loop diuretics bumetanide and furosemide are the only FDA-approved drugs that
modulate the KCCs [172]. In a mouse model study, bumetanide is demonstrated to be
involved in the stimulation of KCC3 expression and subsequent extrusion of [Cl−]i in
the sensory neurons [114]. In addition, Adragna and co-workers [87] in a cell culture
study substituted Thr991 and Thr1048 residues with alanine at the carboxyl terminus of
KCC3a protein, which prevented inhibitory phosphorylation at the substituted sites and
subsequently triggered increased expression of KCC3a mRNA. Interestingly, the flux
condition accompanied a down-regulation of NKCC1 expression, facilitated by the addition
of ouabain (0.1 mM), and bumetanide (10 µM) to the flux media [87].
However, Delpire and Weaver [171] recently expressed their concerns for the need to
develop modulators of KCC activity to provide insights into KCC modulation as a therapeu-
tic strategy for neurological conditions such as stroke. Unfortunately, these FDA approved
drugs (bumetanide and furosemide) are poor inhibitors of KCCs, with a higher potency for
NKCC1 or NKCC2 (IC50 = 0.5–5.0 µM) in comparison to KCC (IC50 = 50–500 mM) [33,171].
In fact, drugs that can act as weak inhibitors might be better alternatives as complete inhibi-
tion mimics a loss-of-function, which could presumably be harmful for the nervous system.
As the KCC isoforms have different expression patterns and physiological functions, target
specificity in the deployed pharmacological approach is also an issue [172]. In a large
screening effort targeted against KCC2, Delpire et al. [173] was able to identify inhibitory
compounds more potent (3–4x) than the two loop diuretics. However, these compounds are
not ideal drug candidates due to the following reasons: (1) non-specificity to KCC2 as they
concurrently inhibit KCC3, and (2) poor pharmacokinetic properties [173,174]. Meanwhile,
the ability of loop diuretics to reach the CNS/PNS remains obscure [171,172]. Perhaps a
better pharmacological approach would be to develop therapeutic compounds that are
specific modulators of the KCC3. Fortunately, our recently developed novel molecular
compound, ZT-1a, is a SPAK kinase inhibitor that specifically stimulates KCC3 and in-
hibits NKCC1 by decreasing their SPAK-dependent phosphorylation/signaling pathway
in cultured cells and in vivo rat and mouse brains [70] (also see Figure 2). In addition, the
systematic administration of ZT-1a ameliorated phosphorylation of co-transporters and
cerebral edema following ischemia, protect against brain damage and improve neurological
functions after stroke episode [70].
6. Conclusions and Future Directions
The CCCs play crucial roles in regulating neuronal functions. The cotransporters are
key mediators of several and important cellular functions such as cell volume regulation,
trans-epithelial ion transport, and maintenance of [Cl−]i. Modulation of NKCC1 and KCC3
expressions by their upstream regulator, WNK-SPAK/OSR1 is implicated in the develop-
ment and progression of stroke. There are several demonstrations that phosphorylation of
NKCC1 and KCC3 via the WNK-SPAK/OSR1 signaling may lead to activation of NKCC1
and inhibition of KCC3 either during or post-stroke episode. In fact, the role of NKCC1
and KCC3 as well as their regulatory proteins in stroke pathogenesis suggests that they
are potential targets for the treatment of stroke. The pharmacological strategies that were
discussed in this review possess potential therapeutic efficacies for stroke management.
Novel compounds must successfully address concerns regarding off-target effects due
to the many isoforms and physiological function related to the WNK-SPAK/OSR1-CCC
pathway. As advances in stroke therapy may also benefit other neurological impairments,
we strongly suggest consistent follow-up actions on currently available pharmacological
treatments for stroke through detailed research studies to aid further development of
therapeutic drugs with a better pharmacokinetic profile. Hence, we holistically advocate
for increased focus on human clinical research on this topic as informed by its paucity to
that regards.
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